查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1608951

肺癌基因组检测市场：按技术、样本类型、组合类型、最终用户划分 - 全球预测 2025-2030

Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction), Sample Type (Liquid Biopsy, Tissue Biopsy), Panel Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肺癌基因组检测市场2023年估值为10.1亿美元，预计到2024年将达到10.7亿美元，复合年增长率为8.00%，到2030年将达到17.3亿美元。

肺癌基因组检测是个人化医疗的重要组成部分，有助于识别与肺癌相关的基因突变。肺癌基因组检测的需求源于客製化治疗、预测疾病进展和改善患者治疗结果的能力，从而使肿瘤学家、医疗保健提供者和研究人员受益。应用范围包括诊断实验室、医院和专注于精准医学的研究机构。关键的成长要素包括肺癌盛行率的增加、定序技术的进步以及对个人化治疗方案的认识增强。新的商机

主要市场统计
基准年[2023] 10.1亿美元
预测年份 [2024] 10.7亿美元
预测年份 [2030] 17.3亿美元
复合年增长率（%） 8.00%

市场动态：快速发展的肺癌基因组检测市场的关键市场洞察

供需的动态交互作用正在改变肺癌基因组检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球癌症病例数不断增加
    • 政府努力扩大肺癌治疗范围
    • 增加研究活动和合作以扩大癌症治疗和预防
  • 市场限制因素
    • 基因检测服务高成本且缺乏报销
  • 市场机会
    • 下一代基因组定序的进展
    • 个人化医疗和生物标记测试的采用趋势
  • 市场挑战
    • 关于基因和分子检测的严格规定

波特五力：引领肺癌基因组检测市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肺癌基因组检测市场的外部影响

外部宏观环境因素在塑造肺癌基因组检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肺癌基因组检测市场的竞争格局

肺癌基因组检测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵肺癌基因组检测市场供应商绩效评估

FPNV定位矩阵是评估肺癌基因组检测市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製肺癌基因组检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肺癌基因组检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的癌症病例数正在增加
      • 政府努力扩大肺癌治疗范围
      • 增加研究活动和合作以扩大癌症治疗和预防
    • 抑制因素
      • 基因检测服务高成本且无法报销
    • 机会
      • 下一代基因定序的进展
      • 个人化医疗的趋势和生物标记测试的引入
    • 任务
      • 关于基因和分子检测的严格规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肺癌基因组检测市场：依技术分类

  • 萤光原位杂合反应
  • 次世代定序
  • 聚合酵素链锁反应

第七章依样本类型分類的肺癌基因组检测市场

  • 液态生物检体
  • 组织切片检查

第八章按面板类型分類的肺癌基因组检测市场

  • 多基因面板
  • 单基因组

第九章肺癌基因组检测市场：依最终用户分类

  • 诊断实验室
  • 医院/诊所
  • 研究机构

第十章 南北美洲肺癌基因组检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区肺癌基因组检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲肺癌基因组检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Admera Health
  • Agilent Technologies, Inc.
  • BGI
  • CD Genomics
  • CeGaT GmbH
  • Centogene NV
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • OncoDNA
  • OPKO Health, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific, Inc.
  • Veracyte, Inc.
Product Code: MRR-7C31448F0BA8

The Lung Cancer Genomic Testing Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.07 billion in 2024, and is projected to grow at a CAGR of 8.00%, to USD 1.73 billion by 2030.

Lung cancer genomic testing is a crucial segment within personalized medicine, aiding in the identification of genetic mutations associated with lung cancer. The need for genomic testing in lung cancer is driven by its ability to tailor treatments, predict disease progression, and enhance patient outcomes, serving oncologists, healthcare providers, and researchers. The application scope encompasses diagnostic labs, hospitals, and research institutes focusing on precision medicine. Key growth factors include the rising prevalence of lung cancer, advancements in sequencing technologies, and increasing awareness of personalized treatment options. Emerging opportunities are

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.07 billion
Forecast Year [2030] USD 1.73 billion
CAGR (%) 8.00%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of cancer incidences across the world
    • Government initiatives to expand access to lung cancer treatment
    • Growing number of research activities and collaborations to expand cancer care and prevention
  • Market Restraints
    • High cost of genetic testing services and the lack of reimbursement
  • Market Opportunities
    • Advancements in next-generation genome sequencing
    • Inclination toward adoption of personalized medicine and biomarker testing
  • Market Challenges
    • Stringent regulations concerning genetic and molecular testing

Porter's Five Forces: A Strategic Tool for Navigating the Lung Cancer Genomic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lung Cancer Genomic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lung Cancer Genomic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lung Cancer Genomic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lung Cancer Genomic Testing Market

A detailed market share analysis in the Lung Cancer Genomic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lung Cancer Genomic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lung Cancer Genomic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lung Cancer Genomic Testing Market

A strategic analysis of the Lung Cancer Genomic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Genomic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Fluorescence In Situ Hybridization, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Sample Type, market is studied across Liquid Biopsy and Tissue Biopsy.
  • Based on Panel Type, market is studied across Multi-Gene Panel and Single-Gene Panel.
  • Based on End User, market is studied across Diagnostic Laboratories, Hospitals/Clinics, and Research Organization.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer incidences across the world
      • 5.1.1.2. Government initiatives to expand access to lung cancer treatment
      • 5.1.1.3. Growing number of research activities and collaborations to expand cancer care and prevention
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of genetic testing services and the lack of reimbursement
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation genome sequencing
      • 5.1.3.2. Inclination toward adoption of personalized medicine and biomarker testing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations concerning genetic and molecular testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lung Cancer Genomic Testing Market, by Technology

  • 6.1. Introduction
  • 6.2. Fluorescence In Situ Hybridization
  • 6.3. Next-Generation Sequencing
  • 6.4. Polymerase Chain Reaction

7. Lung Cancer Genomic Testing Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Liquid Biopsy
  • 7.3. Tissue Biopsy

8. Lung Cancer Genomic Testing Market, by Panel Type

  • 8.1. Introduction
  • 8.2. Multi-Gene Panel
  • 8.3. Single-Gene Panel

9. Lung Cancer Genomic Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals/Clinics
  • 9.4. Research Organization

10. Americas Lung Cancer Genomic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lung Cancer Genomic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Admera Health
  • 3. Agilent Technologies, Inc.
  • 4. BGI
  • 5. CD Genomics
  • 6. CeGaT GmbH
  • 7. Centogene N.V.
  • 8. F. Hoffmann-La Roche AG
  • 9. Illumina, Inc.
  • 10. Laboratory Corporation of America Holdings
  • 11. NeoGenomics Laboratories
  • 12. OncoDNA
  • 13. OPKO Health, Inc.
  • 14. QIAGEN N.V.
  • 15. Quest Diagnostics Incorporated
  • 16. Thermo Fisher Scientific, Inc.
  • 17. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUNG CANCER GENOMIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MULTI-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SINGLE-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023